The demonstration that the actions of GLP-1 are reduced in T2DM [22] led to the development of incretin-based therapies, including GLP-1 receptor agonists (RAs) and dipeptidyl peptidase 4 (DPP-4) inhibitors. The gene discussed is GCG; the disease is type 2 diabetes mellitus.